Scientists at USA Elixiria Biotech Inc. and colleagues described data from preclinical studies evaluating the potential of the peroxisome proliferator-activated receptor γ (PPARγ) agonist, ELB-00824, for protection against chemotherapy-induced neuropathic pain (CINP).
Voronoi Inc. has identified heteroaryl compounds acting as HER2 (erbB2) and/or HER4 (erbB4) inhibitors reported to be useful for the treatment of cancer.
Nuvation Bio Inc. has disclosed drug conjugates comprising a nuclear receptor-targeting moiety covalently linked to a poly(ADP-ribose) polymerase 1 (PARP1) and/or PARP2 inhibitor though a linker. They are reported to be potentially useful for the treatment of cancer.
Merck KGaA and Cancer Research Technology Ltd. have synthesized 2,8-dihydropyrazolo[3,4-b]indoles acting as transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) interaction inhibitors reported to be useful for the treatment of cancer, cardiovascular disorders and liver fibrosis.
Regulatory T cells (Tregs) are known suppressors of immunity activation in the tumor microenvironment, and a high density of Tregs is tied to a poor response to cancer immunotherapy, with CCR8+ Tregs identified as being highly suppressive. Ctm Bio Co. therefore have studied the CCR8 antagonist antibody CTM-033 in preclinical cancer models.
Killer cell immunoglobulin-like receptor 3DL3 (KIR3DL3) is a member of the killer cell Ig-like (KIR) receptor family. When KIR3DL3 is expressed on T and natural killer (NK) cells in the tumor microenvironment, it suppresses immune responses following engagement with HHLA2, suggesting that the KIR3DL3-HHLA2 axis potentially represents a novel immune checkpoint pathway and that blockade of KIR3DL3 signaling could promote antitumor immunity.
Chengdu Easton Biopharmaceuticals Co. Ltd. has described proteolysis targeting chimera (PROTAC) compounds comprising a cereblon (CRBN) ligand binding moiety covalently bound to a bromodomain-containing protein 4 (BRD4; HUNK1)-targeting moiety through a linker.
Bionova Pharmaceuticals Ltd. has identified heteroaromatic carboxamide compounds acting as Bruton tyrosine kinase (BTK) and BTK (C481S mutant) inhibitors reported to be useful for the treatment of asthma, cancer, graft-vs.-host disease, inflammatory bowel disease, psoriasis, thrombotic thrombocytopenic purpura, rheumatoid arthritis and autoimmune thyroiditis, among others.
RSS
